Navigation Links
Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

eive infusions of REMICADE 5 mg/kg at weeks 0, 2 and 6 and every six weeks thereafter through week 96 (n = 201) or placebo (n = 78). The primary endpoint of the trial was a 20 percent decrease in disease activity score on the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20) at week 24.

At week 24, placebo patients were crossed over to receive treatment with REMICADE 5 mg/kg at weeks 0, 2 and 6 and every six weeks thereafter and continued on REMICADE through the remainder of the study (96 weeks). Starting at week 36, and continuing through week 96, patients initially randomized to receive REMICADE 5 mg/kg had their dose increased to 7.5 mg/kg if they had a BASDAI of at least 3 in two consecutive evaluations to assess the potential for improved response through increased dosing. Using these rather strict criteria, 106 patients (53 percent) received a dose increase some time after week 30.

Nine percent of patients who received REMICADE through week 102 discontinued the study due to adverse events (AEs). During the study, REMICADE was generally well-tolerated. At week 24, the most commonly reported AEs were upper respiratory tract infections, which occurred at a rate of 15 percent in the placebo group, compared with 14 percent in the REMICADE group. The only laboratory abnormalities that occurred more frequently with REMICADE compared with placebo were asymptomatic liver enzyme test elevations. At week 24, serious (AEs) were reported in 4 percent of REMICADE-treated patients, compared with three percent of patients receiving placebo. AEs were generally mild and were consistent with REMICADE prescribing information.

There were no reports of congestive heart failure, tuberculosis or serious infections in the study population. Three malignancies were reported in three patients during the ASSERT study and included squamous cell skin cancer, lung cancer and breast cancer. Please see "Important Safety Information" below.

About Ankyl
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation
Post Your Comments:
(Date:9/22/2014)... 22, 2014  For many people experiencing issues ... facing the prospect of large, painful incisions and ... activities are also impacted, such as working, driving ... the problem, some patients even delay necessary treatment, ... lead to permanent damage for some conditions. ...
(Date:9/22/2014)... 22, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... announce that TUV-SUD and The Medicinal Evaluation Board ... has granted its request for a label expansion ... initially approved in July 2013 for use in ...
(Date:9/22/2014)... -- Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, announced today that ... and Chief Executive Officer, effective immediately.  Mr. Grossman succeeds ... his executive and Board roles but will remain as ... of 2016.  Mr. Grossman has served ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5
...  Merrimack Pharmaceuticals, Inc. announced today that the first ... clinical study combining MM-121, a fully human monoclonal ... irinotecan (Camptosar®) in patients with advanced cancers. ... The Phase 1 study evaluates the safety and ...
... Md., Dec. 13, 2011 The U.S. Food and ... device intended to aid in the detection of life-threatening ... spectroscopy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... health care providers identify patients with critical head injuries ...
Cached Medicine Technology:Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers 2FDA Permits Marketing of the First Hand-Held Device To Aid in the Detection of Bleeding In The Skull 2FDA Permits Marketing of the First Hand-Held Device To Aid in the Detection of Bleeding In The Skull 3
(Date:9/22/2014)... South Asians living in Canada have a higher rate ... compared with while people, McMaster researchers have found. ... Canadian Medical Association Journal (CMAJ Open) and may ... the fastest-growing ethnic groups in the country is the ... Canada, comprising about three percent of the population. They ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 CareFlight ... has taken delivery of a new AS365 N3+ Dauphin, ... helicopter. The new aircraft, which is based at ... all-Dauphin fleet of four air medical transport helicopters. , ... said Candy Skidmore, Premier Health Vice President, Emergency, Trauma, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... 24 Catholic Charities,USA today urged Congress and ... come together to pass a comprehensive children,s health,insurance ... to vote on a compromise bill to,reauthorize the ... program that provides health insurance coverage to poor,children. ...
... and S.E.VEN, BOSTON, Sept. 24 Small Army, ... a cure for diabetes and,alleviating world poverty to their ... and S.E.VEN. "As communicators, we welcome the challenge ... dollars, but by a commitment,to truly make the world ...
... to Execute and Completeness of Vision, ANDOVER, ... management (IAM) solutions are the most widely implemented ... in the Visionaries,quadrant by Gartner, Inc. in the ... of the Magic Quadrant for User Provisioning, 2H07,(authored ...
... a,leading technology provider of mobile enterprise solutions for ... NASDAQ Stock,Market LLC has approved its application for ... Capital Market. Trading in the Company,s common stock,commenced ... the symbol "IFLG." (Logo: http://www.newscom.com/cgi-bin/prnh/20060209/PHTH052LOGO ...
... CHASKA, Minn., Sept. 24 Tired? Stressed? ... restore, and rejuvenate? The Village Company,( http://www.thevillagecompany.com ... bath,and body products, announces the nationwide launch ... relief from common ailments,( http://www.thevillagecompany.com/vntherapy.html ). ...
... Novo Nordisk, a,world leader in diabetes care, ... the Dow Jones Sustainability World Index (DJSI World) ... 18 global supersectors,analyzed. The latest global analysis ... analysis of companies, economic, environmental and,social performance, assessing ...
Cached Medicine News:Health News:Catholic Charities USA Calls on Congress and the President to Protect the Health of Children; Urges President Not to Veto Vitally Important Bill 2Health News:Catholic Charities USA Calls on Congress and the President to Protect the Health of Children; Urges President Not to Veto Vitally Important Bill 3Health News:Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts 2Health News:Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firm's User Provisioning Magic Quadrant 2Health News:Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firm's User Provisioning Magic Quadrant 3Health News:InfoLogix Announces Approval for NASDAQ Listing 2Health News:InfoLogix Announces Approval for NASDAQ Listing 3Health News:The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments 2Health News:Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes 2
... of fibre bronchoscopy: The HF-compatible V series ... other fibre bronchoscopes are measured., ,The ... including the FB-19TV, FB-18V and FB-15V models ... the pediatric FB-8V, offer much better image ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Slim bronchoscope designed for paediatric applications....
Medicine Products: